Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis.
J Clin Rheumatol
; 25(5): 217-223, 2019 Aug.
Article
in En
| MEDLINE
| ID: mdl-30896460
ABSTRACT
INTRODUCTION:
The value of antineutrophil cytoplasmic antibody (ANCA) measurements among patients with an established diagnosis of ANCA-associated vasculitis (AAV) to assess disease activity or predict relapse remains controversial, but recent evidence suggests a possible role for rituximab-treated patients. PATIENTS ANDMETHODS:
All patients with active vasculitis and positive proteinase 3 (PR3)-ANCA who were starting a 2-year treatment course of rituximab for induction of remission at Addenbrooke's Hospital between January 2011 and January 2016 were included in this study. Common department practice consists of 6 g of rituximab given over 2 years, concomitant corticosteroids (0.5-1.0 mg/kg) with rapid taper over 3 months, and cessation of oral maintenance immunosuppressive agents at time of first rituximab dose. Clinical and laboratory data were collected retrospectively using electronic patient records.RESULTS:
Fifty-seven patients with current PR3-ANCA positivity were included in the analysis. Median follow-up was 59 months. PR3-ANCA negativity was achieved in 25 patients (44%) with a median time of 14 months. Clinical remission was achieved in 53 patients (93%) with a median time of 3 months. Among the 53 patients who achieved remission during follow-up, 24 (45%) relapsed with a median time to relapse of 36 months from remission. Both PR3-ANCA-negative status and 50% reduction in PR3-ANCA from baseline (as time-varying covariates) were significantly associated with a longer time to relapse (PR3-ANCA-negative status hazards ratio, 0.08 [95% confidence interval, 0.01-0.63, p = 0.016]; 50% reduction in PR3-ANCA hazards ratio, 0.25 [95% confidence interval, 0.18-0.99, p = 0.046]).CONCLUSIONS:
Achieving and maintaining PR3-ANCA negativity after rituximab was associated with longer-lasting remission.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antibodies, Antineutrophil Cytoplasmic
/
Myeloblastin
/
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
/
Rituximab
/
Immunologic Factors
Type of study:
Prognostic_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Clin Rheumatol
Journal subject:
FISIOLOGIA
/
ORTOPEDIA
/
REUMATOLOGIA
Year:
2019
Type:
Article